Microbot Medical Inc. Relocates Principal Executive Offices

TL;DR

Microbot Medical is moving its main office to Braintree, MA.

AI Summary

Microbot Medical Inc. filed an 8-K on June 17, 2024, to report on other events and financial statements. The filing indicates a change in the company's principal executive offices to 288 Grove Street, Suite 388, Braintree, MA 02184. The company was formerly known as STEMCELLS INC and CYTOTHERAPEUTICS INC/DE.

Why It Matters

This filing signals a change in the company's operational base, which could impact logistics, employee access, and potentially future expansion plans.

Risk Assessment

Risk Level: low — The filing primarily concerns a change of address for the company's principal executive offices, which is a routine administrative event.

Key Players & Entities

• Microbot Medical Inc. (company) — Registrant
• June 17, 2024 (date) — Date of earliest event reported
• 288 Grove Street, Suite 388, Braintree, MA 02184 (location) — New Principal Executive Offices
• STEMCELLS INC (company) — Former Company Name
• CYTOTHERAPEUTICS INC/DE (company) — Former Company Name

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value MBOT NASDAQ Capital Mark

Filing Documents

• form8-k.htm (8-K) — 43KB
• ex99-1.htm (EX-99.1) — 12KB
• ex99-1_001.jpg (GRAPHIC) — 6KB
• 0001493152-24-024041.txt ( ) — 238KB
• mbot-20240617.xsd (EX-101.SCH) — 3KB
• mbot-20240617_lab.xml (EX-101.LAB) — 33KB
• mbot-20240617_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 4KB

01 of this Current Report on Form 8-K contains "forward-looking statements." Such statements which are not purely

Item 8.01 of this Current Report on Form 8-K contains "forward-looking statements." Such statements which are not purely historical (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "intends," "would," "could" and "estimates") are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, regulatory milestones. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this Form 8-K, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Although the Company believes that the beliefs, plans, expectations and intentions contained in this Form 8-K are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the Company's reports and statements filed from time-to-time with the Securities and Exchange Commission. Item 9.01. Financial (d) Exhibits Exhibit Number Description 99.1 Press Release 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. MICROBOT MEDICAL INC. By: /s/ Harel Gadot Name: Harel Gadot Title: Chief Executive Officer, President and Chairman Date: June 17, 2024

View Full Filing

View this 8-K filing on SEC EDGAR